Healthcare Equipment and Supplies
Company Overview of CardioKinetix, Inc.
CardioKinetix, Inc. operates as a medical device company that develops catheter-based treatment devices to treat congestive heart failures resulting from a heart attack in patients. The company offers a partitioning device deployed within the left ventricle (for ischemic left sided heart failure patients) that partitions damaged muscles by isolating the non-functional muscle segment from the functional segment; MRI-related heating products; parachute delivery components; percutaneous ventricular restoration therapies; and ventricular restoration products. It serves customers worldwide. The company was incorporated in 2002 and is headquartered in Menlo Park, California.
925 Hamilton Avenue
Menlo Park, CA 94025
Founded in 2002
Key Executives for CardioKinetix, Inc.
Vice President of Operations
Vice President of Clinical
Compensation as of Fiscal Year 2014.
CardioKinetix, Inc. Key Developments
CardioKinetix, Inc. Releases Results of a Pooled Analysis Study of Parachute Ventricular Partitioning Device
Sep 16 14
CardioKinetix Inc. announced results of a pooled analysis study of the first-of-its-kind catheter-based Parachute(R) Ventricular Partitioning Device. Twelve-month clinical data from PARACHUTE III, a study of 100 post-market European patients with ischemic heart failure treated consecutively between 2011 and 2013, were presented at the 2014 TCT Conference in Washington, D.C., by Ulrich Schäfer, M.D., cardiology director of the Structural Heart Division at the Heart Center at the University Medical Center Hamburg-Eppendorf, and at the 2014 HFSA Conference in Las Vegas, Nev., by William Abraham, M.D., professor of internal medicine and director of the Division of Cardiovascular Medicine at Ohio State University Medical Center. Parachute had a very high procedural success rate of 97% (97/100). The twelve-month highlights from the data include: Primary safety endpoint yielded a low 7% rate of device- or procedure-related MACCE. Sustained reduction of left ventricle volumes (p < 0.0001) resulting in significant improvements in systolic function and a significant reduction in left atrial volume (p < 0.05) reflected improved diastolic function. NYHA functional class improved or maintained in 80% of patients. Six-minute walk distance improved at follow-up (p < 0.01), with 46% of patients walking an additional 20 meters or more. Rates of death and the combined endpoint of death and repeat hospitalization for heart failure were 9.5% and 26.0%, respectively.
Cardiokinetix Provides Update on Parachute Iv, the Randomized Pivotal U.S. Trial of the Minimally Invasive Parachute Ventricular Partitioning Device for the Treatment of Heart Failure
Jan 8 13
CardioKinetix, Inc. announced the enrollment of the first patients in PARACHUTE IV, the randomized pivotal U.S. trial of the minimally invasive Parachute(TM) Ventricular Partitioning Device for the treatment of heart failure. PARACHUTE IV is a multi-center pivotal trial designed to evaluate the PARACHUTE implant vs. optimal medical therapy (randomized 1:1) in approximately 500 patients with ischemic heart failure at up to 65 centers. The event-driven primary endpoint includes all-cause mortality and hospitalization for worsening heart failure. Other key endpoints include functional outcomes, quality of life, and hemodynamic measures by echocardiography. The first implant with the Parachute device was performed by David Mego, M.D., assistant medical director at Arkansas Heart Hospital in Little Rock, Arkansas, who treated a 39-year-old female with NYHA class III heart failure referred by Carl Leding, M.D., director of the Congestive Heart Failure Clinic at Arkansas Heart Hospital.
Cardiokinetix, Inc. Receives CE Mark Approval for Full Range of Sizes for Percutaneous Treatment for Heart Failure
Oct 23 12
CardioKinetix, Inc. announced it has received CE Mark approval for the full size matrix of its Parachute(TM) Ventricular Partitioning Device for Percutaneous Ventricular Restoration (PVR) therapy. The CE Mark approval for the full matrix of sizes of the Parachute implant is an important milestone; it will enable to provide this innovative treatment to a wide range of heart failure patients in the European Union. The Parachute device has been used in approximately 90 cases to date. Clinical results showing safety and meaningful and sustained low clinical events for patients with ischemic heart failure three years following treatment with the Parachute Ventricular Partitioning Device were presented at the 2012 European Society of Cardiology Conference in Munich in August. The first-of-its-kind Parachute Ventricular Partitioning Device is a minimally invasive treatment for patients with heart failure caused by damage to the heart muscle following a heart attack. Clinical data demonstrates improved overall cardiac function and quality of life for patients treated with the Parachute device. Through a small catheter inserted in the femoral artery, the Parachute implant is deployed in the left ventricle to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its geometry and function. This minimally invasive procedure is performed in the catheterization laboratory under conscious sedation. The Parachute Ventricular Partitioning Device received CE Mark in 2011. In the U.S., the Parachute system is an investigational device limited by federal law to investigational use only and is not available for sale.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|